Evidence map›Paper›PMID 29313255›Full record

ArticleBiotechnology letters2018

Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice.

Zeinab Panahi, Asghar Abdoli, Ghasem Mosayebi, Mehdi Mahdavi, Fariborz Bahrami

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zeinab PanahiDepartment of Microbiology and Immunology, School of Medicine, Molecular and Medicine Research Center (MMRC), Arak University of Medical Sciences, P.O. Box: 38481-7-6941, Arak, Iran.
Asghar AbdoliDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Ghasem MosayebiDepartment of Microbiology and Immunology, School of Medicine, Molecular and Medicine Research Center (MMRC), Arak University of Medical Sciences, P.O. Box: 38481-7-6941, Arak, Iran. ghasemmosayebi@arakmu.ac.ir.
Mehdi MahdaviDepartment of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Fariborz BahramiDepartment of Immunology, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the combined effects of CpG oligodeoxynucleotides (CpG-ODNs) adjuvant and subcutaneous injection route on efficacy of a HIV-1-tat DNA vaccine candidate using BALB/c mice as an animal model.

resultsEvaluation of cellular and humoral immunity of mice injected subcutaneously with HIV-1-tat gene cloned into a pcDNA3.1 vector indicated that significant levels of IFN-γ cytokine secretion (900 pg/ml), lymphocyte proliferation (2.5 stimulation index) and IgG

conclusionsFormulation of HIV-1-tat DNA vaccine candidate with CpG-ODNs as an adjuvant while administrated subcutaneously are a promising approach to induce effective cellular immunity responses against HIV-1 infection.

Indexed as

Adjuvants, ImmunologicAIDS VaccinesAnimalsCell ProliferationFemaleHIV-1Injections, SubcutaneousInterferon-gammaMiceMice, Inbred BALB COligodeoxyribonucleotidesVaccines, DNAAdjuvants, ImmunologicAIDS VaccinesCPG-oligonucleotidehuman immunodeficiency virus type 1 Tat vaccineInterferon-gammaOligodeoxyribonucleotidesVaccines, DNACpG-ODNsDNA vaccineHIV-1HIV vaccineSubcutaneous injectionTat

Identifiers

PMID29313255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.